COS-ID-based imprinted polymers with carbohydrate–metal–epitope synergy for selective MMP-9 detection in cancer patient serum

🔗 원문 전체 보기 → Royal Society of Chemistry

요약

Anal. Methods, 2026, Advance ArticleDOI: 10.1039/D6AY00486E, PaperMei Tian, Xue Dong, Yu Cheng, Miaomiao Zhang, Qian Xu, Zehui Wei, Suhong WangCOS-ID-based imprinted polymers realize the selective recognition of MMP-9 via synergistic carbohydrate-metal-epitop…

본문

COS-ID-based imprinted polymers with carbohydrate–metal–epitope synergy for selective MMP-9 detection in cancer patient serum

* Corresponding authors

a College of Pharmacy, Jiangsu Ocean University, Lianyungang 222005, China
E-mail: [email protected], [email protected]

b Jiangsu Marine Resources Development Technology Innovation Center, Lianyungang 222005, China

c Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang 222005, China

d Ganyu District People's Hospital of Lianyungang City, Lianyungang 222005, Jiangsu Province, China

e Clinical Laboratory, Liaocheng Veterans Hospital, Liaocheng 252000, Shandong Province, China

Abstract

To address the insufficient specificity and lack of glycosylation-dependent recognition of conventional molecularly imprinted polymers (MIPs) for matrix metalloproteinase-9 (MMP-9) pretreatment in complex serum, biomimetic epitope-imprinted polymers were prepared using a novel chitosan oligosaccharide-imine derivative (COS-ID). A “carbohydrate–metal–epitope” synergistic system was constructed via multi-site hydrogen bonding, Zn2+ dual-site coordination, and 3D cavity imprinting, enabling highly specific recognition of MMP-9. Under optimized conditions, the COS-ID-based MIPs achieved a maximum adsorption capacity of 48.59 mg g−1, and an imprinting factor of 4.26, with 94.15% reusability after five cycles. After 36 weeks of storage, the MIPs retained 96.81% of their initial adsorption capacity, with the imprinting factor slightly declining from 4.44 to 4.16, confirming satisfactory long-term stability. The adsorption behavior fitted well to the pseudo-second-order kinetic (R2 = 0.9987) and Langmuir isotherm models (R2 = 0.9753), with relatively high selectivity toward MMP-9. Recoveries were 90.56–92.13% for spiked human serum (avg.: 91.56%, RSD = 0.95%, n = 3) and 82.35–115.02% for clinical cancer patient serum (avg.: 95.42%, RSD = 0.30–2.53%, n = 3), with most values complying with FDA/EMA acceptance criteria. Benefiting from their polysaccharide backbone and functional groups, the MIPs exhibited satisfactory biocompatibility and anti-matrix interference capacity. This low-cost, selective, and long-term stable MIP platform offers a promising alternative to antibody-based methods for the pretreatment and analysis of MMP-9 in complex clinical serum matrices.

• This article is part of the themed collection: Analytical Methods HOT Articles 2026